Clinicians are advised of potential atypical cases of diabetic ketoacidosis resulting from SGLT2 inhibitor use for type 2 diabetes mellitus treatment.
Mark L. Fuerst
Sleep habits may help identify patients who could benefit from diabetes-prevention programs.
Does testosterone treatment exacerbate the risk of cardiovascular events in men with type 2 diabetes and a high risk of cardiovascular events?
Physical activity is considered a key strategy for the prevention of type 2 diabetes, but how much is needed and what is its effect?
As the age of type 2 diabetes onset decreases, the need for primary prevention of CV complications increases – as illustrated in a recent study.
Can a new algorithm, using parameters such as life expectancy and cognitive function, determine individualized glycemic goals for T2DM patients?
A new tool that calculates risks of certain diabetes complications could help your patients make more informed decisions about their treatment.
The verdict is in regarding SGLT2 inhibitor use and diabetic ketoacidosis. Expert panel conclusions are summarized.
Does high-intensity exercise lead to high cardiometabolic rewards in a type 2 diabetes population?
Changes in CV risk factors, low frequency of hypoglycemic events, and a protective renal effect are a few benefits found with SGLT2 inhibitors.